Andrew W. Eller, MD, was educated at Pennsylvania State University and obtained his medical degree from Drexel University College of Medicine, formerly Hahnemann Medical College. He completed his residency in ophthalmology at Wills Eye Hospital, Thomas Jefferson University in Philadelphia, and obtained fellowship training in vitreoretinal diseases with the Retina Associates, Eye Research Institute of Retina Foundation, and Massachusetts Eye & Ear Infirmary.
Following his training, Dr. Eller joined the full-time faculty in the Department of Ophthalmology at the University of Pittsburgh School of Medicine in 1985 as an assistant professor. Over the past nearly 40 years, he has risen through the academic ranks to professor. He currently serves as the Director of the Retina and Ocular Trauma Services, and as the program director for the vitreo-retinal fellowship at the UPMC Vision Institute. Dr. Eller is certified by the American Board of Ophthalmology and has served as an associate oral board examiner for more than 20 years. He is a member of The Retina Society and the American Society of Retinal Specialists.
Dr. Eller has taught and mentored numerous medical students, residents, and fellows, and he has been honored with various teaching awards. He has authored or co-authored over 70 papers in the peer-reviewed literature and has served as a reviewer for multiple ophthalmic journals. In addition to his teaching and providing clinical care, he has served in numerous organizations, including the Pittsburgh Ophthalmology Society, and as a board member of the Pennsylvania Academy of Ophthalmology (PAO). He represented the PAO on the Council of the American Academy of Ophthalmology (AAO) and served a term on the Secretariat of State Affairs of the AAO. His special interests are in the treatment of diabetic retinopathy, macular degeneration, retinal detachment, ocular trauma, and AIDS-related eye diseases.
- Eye Research Institute of Retina Foundation, Massachusetts Eye & Ear Infirmary, and Retina Associates, Vitreoretinal Diseases Fellowship
- Wills Eye Hospital Department of Ophthalmology Thomas Jefferson University, Residency
- Presbyterian-University of Pennsylvania Medical Center, Internship
- Hahnemann Medical College, MD
- Pahlavi University, Medical School; Shiraz, Iran, MD
- Pennsylvania State University, BS in Biology
Education & Training
2000-Present
Co-Investigator,
A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR).
Total three-year budget $274,483. Novartis.
2000-Present
Use of a non-mydriatic panoramic imaging device.
Optos Corporation
$55,000.
1999-Present
Co-Investigator
A Phase III randomized, multi-center, double masked, placebo controlled parallel group study with Tin Ethyl Etiopuryltin photodynamic therapy in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.
Miravant Medical Technologies, Estimated $100,000 x 3 years
1997-Present
Co-Investigator
Prophylactic Diode Laser Photocoagulation for the Prevention of Choroidal Neovascularization in Age-Related Macular Degeneration.
IRB No. 950505.
Eye and Ear Foundation of Pittsburgh, $50,000/year x 3 years.